Baricitinib Attenuates Autoimmune Phenotype and Podocyte Injury in a Murine Model of Systemic Lupus Erythematosus

OBJECTIVE: Baricitinib, a selective inhibitor for janus kinase (JAK) 1 and JAK2, is approved for use in rheumatoid arthritis. Systemic lupus erythematosus (SLE) is recently regarded as a potential candidate targeted by JAK inhibitors because of the relationship between its pathogenesis and JAK/signa...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jaeseon, Park, Youngjae, Jang, Se Gwang, Hong, Seung-Min, Song, Young-Seok, Kim, Min-Jun, Baek, SeungYe, Park, Sung-Hwan, Kwok, Seung-Ki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419414/
https://www.ncbi.nlm.nih.gov/pubmed/34497607
http://dx.doi.org/10.3389/fimmu.2021.704526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419414/
https://www.ncbi.nlm.nih.gov/pubmed/34497607
http://dx.doi.org/10.3389/fimmu.2021.704526

Ejemplares similares